Mark A. Miller

4.8k total citations · 1 hit paper
41 papers, 3.6k citations indexed

About

Mark A. Miller is a scholar working on Epidemiology, Infectious Diseases and Modeling and Simulation. According to data from OpenAlex, Mark A. Miller has authored 41 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 16 papers in Infectious Diseases and 14 papers in Modeling and Simulation. Recurrent topics in Mark A. Miller's work include Influenza Virus Research Studies (21 papers), COVID-19 epidemiological studies (14 papers) and Vaccine Coverage and Hesitancy (11 papers). Mark A. Miller is often cited by papers focused on Influenza Virus Research Studies (21 papers), COVID-19 epidemiological studies (14 papers) and Vaccine Coverage and Hesitancy (11 papers). Mark A. Miller collaborates with scholars based in United States, Canada and Switzerland. Mark A. Miller's co-authors include Roger I. Glass, Umesh D. Parashar, Erik Hummelman, Joseph Bresee, Cécile Viboud, Lone Simonsen, Richard H. Rahe, Robert J. Taylor, Lisa A. Jackson and Laura McCann and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Mark A. Miller

39 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global Illness and Deaths Caused by Rotavirus Disease in Children

2003 1.5k citations Mark A. Miller et al. profile →

Peers

Mark A. Miller

ID

EPIDE

CCM

HEPAT

MS

Charles W. LeBaron United States

Anthony Burton Switzerland

Paul A. Gastañaduy United States

Kristine Macartney Australia

Tasnim Azim Bangladesh

Ángela Domı́nguez Spain

Benjamin A. Lopman United States

Eyal Leshem Israel

Mary Allen Staat United States

Aiqiang Xu China

Charles W. LeBaron United States

Mark A. Miller

1.8k ×0.8

ID

1.6k ×1.2

EPIDE

473 ×0.6

CCM

462 ×0.6

HEPAT

211 ×0.4

MS

Citations per year, relative to Mark A. Miller Mark A. Miller (= 1×) peers Charles W. LeBaron

Countries citing papers authored by Mark A. Miller

Since Specialization

Citations

This map shows the geographic impact of Mark A. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Miller more than expected).

Fields of papers citing papers by Mark A. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Miller. The network helps show where Mark A. Miller may publish in the future.

Co-authorship network of co-authors of Mark A. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Miller. A scholar is included among the top collaborators of Mark A. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Miller. Mark A. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Hoest, Christel, Jessica C. Seidman, Gwenyth Lee, et al.. (2016). Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study. Vaccine. 35(3). 443–451. 39 indexed citations

2.

Chowell, Gerardo, Lone Simonsen, Sherry Towers, Mark A. Miller, & Cécile Viboud. (2013). Transmission potential of influenza A/H7N9, February to May 2013, China. BMC Medicine. 11(1). 214–214. 44 indexed citations

3.

Mahamat, Aba, Philippe Dussart, Séverine Matheus, et al.. (2013). Climatic drivers of seasonal influenza epidemics in French Guiana, 2006–2010. Journal of Infection. 67(2). 141–147. 26 indexed citations

4.

Schuck‐Paim, Cynthia, Cécile Viboud, Lone Simonsen, et al.. (2012). Were Equatorial Regions Less Affected by the 2009 Influenza Pandemic? The Brazilian Experience. PLoS ONE. 7(8). e41918–e41918. 23 indexed citations

5.

Chowell, Gerardo, Cécile Viboud, Lone Simonsen, et al.. (2011). The 1918–1920 influenza pandemic in Peru. Vaccine. 29. B21–B26. 39 indexed citations

6.

Richard, Stephanie A, Cécile Viboud, & Mark A. Miller. (2010). Evaluation of Southern Hemisphere influenza vaccine recommendations. Vaccine. 28(15). 2693–2699. 24 indexed citations

7.

Simonsen, Lone, Cécile Viboud, Robert J. Taylor, Mark A. Miller, & Lisa A. Jackson. (2009). Influenza vaccination and mortality benefits: New insights, new opportunities. Vaccine. 27(45). 6300–6304. 63 indexed citations

8.

Mello, Wyller Alencar de, Terezinha Maria de Paiva, María Akíko Ishida, et al.. (2009). The Dilemma of Influenza Vaccine Recommendations when Applied to the Tropics: The Brazilian Case Examined Under Alternative Scenarios. PLoS ONE. 4(4). e5095–e5095. 58 indexed citations

9.

Miller, Mark A.. (2007). Clinical Management of Clostridium difficile-Associated Disease. Clinical Infectious Diseases. 45(Supplement_2). S122–S128. 36 indexed citations

10.

Miller, Mark A., et al.. (2006). An Outbreak of Scabies in a Long-Term Care Facility: The Role of Misdiagnosis and the Costs Associated With Control. Infection Control and Hospital Epidemiology. 27(5). 517–518. 52 indexed citations

11.

Viboud, Cécile, Theresa Tam, Douglas Fleming, et al.. (2006). Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic. Vaccine. 24(44-46). 6701–6707. 91 indexed citations

12.

Roberto, Anthony J., et al.. (2005). Adolescents’ knowledge, beliefs, and behaviors regarding hepatitis B: Insights and implications for programs targeting vaccine-preventable diseases. Journal of Adolescent Health. 36(3). 178–186. 45 indexed citations

13.

Miller, Mark A.. (2002). Imported from Cuba?. Canadian Journal of Infectious Diseases and Medical Microbiology. 13(5). 333–340. 1 indexed citations

14.

Miller, Mark A. & Laura McCann. (2000). Policy analysis of the use of hepatitis B,Haemophilus influenzae type b-,Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Economics. 9(1). 19–35. 127 indexed citations

15.

Miller, Mark A.. (2000). Introducing a Novel Model to Estimate National and global measles disease burden. International Journal of Infectious Diseases. 4(1). 14–20. 15 indexed citations

16.

Miller, Mark A.. (1999). Considerations for adding pneumonia and influenza vaccines to public health programmes. Vaccine. 17. S95–S98. 5 indexed citations

17.

Miller, Mark A., Stephen C. Redd, Stephen C. Hadler, & Alan R. Hinman. (1998). A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine. 16(20). 1917–1922. 28 indexed citations

18.

Miller, Mark A. & Richard H. Rahe. (1997). Life changes scaling for the 1990s. Journal of Psychosomatic Research. 43(3). 279–292. 226 indexed citations

19.

Miller, Mark A., Sarah E. Valway, & Ida M. Onorato. (1996). Tuberculosis risk after exposure on airplanes. Tubercle and Lung Disease. 77(5). 414–419. 47 indexed citations

20.

Mendelson, Jack H., et al.. (1995). Human to Human Transmission of Brucella Melitensis. Canadian Journal of Infectious Diseases and Medical Microbiology. 6(3). 153–155. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact